$HKPD
Cellyan Biotechnology Co., Ltd
CIK:0002007702|SEC Filings
Consolidated Statements of Profit or Loss and Other Comprehensive Income - USD ($) |
12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Mar. 31, 2024 |
|||||
| Profit or loss [abstract] | |||||||
| Revenues | $ 13,433,507 | $ 20,313,818 | $ 16,688,364 | ||||
| Cost of revenues | (12,047,198) | (17,898,659) | (13,129,699) | ||||
| Gross profit | 1,386,309 | 2,415,159 | 3,558,665 | ||||
| Other income | 5,327 | 1,466 | 4,038 | ||||
| Operating expenses: | |||||||
| Selling, general and administrative expenses | (2,395,075) | (2,215,859) | (1,889,455) | ||||
| Other gains (losses), net | 8,537 | (68,728) | (64,987) | ||||
| Total operating expenses | (2,386,538) | (2,284,587) | (1,954,442) | ||||
| Operating (loss)/profit | (994,902) | 132,038 | 1,608,261 | ||||
| Financial income | 454 | 1,741 | 474 | ||||
| Finance costs | (133,849) | (97,667) | (82,766) | ||||
| Finance costs, net | (133,395) | (95,926) | (82,292) | ||||
| (Loss)/profit before income taxes | (1,128,297) | 36,112 | 1,525,969 | ||||
| Income tax expense | (7,666) | (63,168) | (196,252) | ||||
| Net (loss)/profit for the year | (1,135,963) | (27,056) | 1,329,717 | ||||
| (Loss)/profit attributable to owners of the Company | (1,135,963) | (27,056) | 1,329,717 | ||||
| Other comprehensive loss | |||||||
| Foreign currency translation adjustments | (20,696) | 15,677 | (516) | ||||
| Comprehensive (loss)/income attributable to the Company’s shareholders | $ (1,156,659) | $ (11,379) | $ 1,329,201 | ||||
| Earnings per share | |||||||
| Basic (in Dollars per share) | [1] | $ (0.069) | $ (0.003) | $ 0.18 | |||
| Diluted (in Dollars per share) | [1],[2] | $ (0.069) | $ (0.003) | $ 0.18 | |||
| Weighted average number of shares outstanding | |||||||
| Basic (in Shares) | [1] | 16,349,986 | 10,205,479 | 7,365,570 | |||
| Diluted (in Shares) | [1],[2] | 16,349,986 | 10,205,479 | 7,365,570 | |||
| |||||||